{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-050327","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.323827+00:00","generated_at":"2026-05-20T01:58:30.560848+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025","bullets":["Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.","Company expects to announce IHL-42X Phase 2 topline data in July 2025.","Phase 3 US study planned to start later in 2025.","IHL-42X is an oral once-daily treatment for obstructive sleep apnea (OSA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-050327","json":"https://secwatch.observer/filing/0001213900-25-050327.json","markdown":"https://secwatch.observer/filing/0001213900-25-050327.md","text":"https://secwatch.observer/filing/0001213900-25-050327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/0001213900-25-050327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/ea0244374-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:58:30.560848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}